We are live on ! Find out more
AQST icon

Aquestive Therapeutics
AQST

184 hedge funds and large institutions have $300M invested in Aquestive Therapeutics in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 69 increasing their positions, 43 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

284% more call options, than puts

Call options by funds: $8.26M | Put options by funds: $2.15M

60% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 43

33% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 18

2% more funds holding

Funds holding: 180 → 184 (+4)

0% more capital invested

Capital invested by funds: $299M → $300M (+$935K)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.51% less ownership

Funds ownership: 58.91% → 57.4% (-1.5%)

Holders
184
Holders Change
+4
Holders Change %
+2.22%
% of All Funds
2.22%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
24
Increased
69
Reduced
43
Closed
18
Calls
$8.26M
Puts
$2.15M
Net Calls
+$6.11M
Net Calls Change
-$1.32M

Top Buyers

Rank Fund Capital Flow
1
Nuveen
Nuveen
North Carolina
+$4.05M
2
PBM
Propel Bio Management
California
+$3.08M
3
BlackRock
BlackRock
New York
+$2.36M
4
WA
Wasatch Advisors
Utah
+$2.14M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.75M

Top Sellers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$9.07M
2
Morgan Stanley
Morgan Stanley
New York
-$3.93M
3
Bank of America
Bank of America
North Carolina
-$3.1M
4
Jane Street
Jane Street
New York
-$2.49M
5
SCM
Sio Capital Management
New York
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
DAFNA Capital Management
California
$2.69M +$1.17M +277,500 +75%
EAM
27
Everstar Asset Management
North Carolina
$2.55M +$247K +58,762 +11%
AIC
28
AWM Investment Company
New York
$1.98M +$863K +205,000 +76%
Goldman Sachs
29
Goldman Sachs
New York
$1.95M +$7.58K +1,802 +0.4%
BCL
30
Bracebridge Capital LLC
Massachusetts
$1.91M – – –
UBS Group
31
UBS Group
Switzerland
$1.91M -$24.4K -5,793 -1%
Citadel Advisors
32
Citadel Advisors
Florida
$1.88M -$476K -113,006 -20%
Jane Street
33
Jane Street
New York
$1.82M -$2.49M -592,560 -58%
Renaissance Technologies
34
Renaissance Technologies
New York
$1.73M +$1.75M +416,248 New
Stifel Financial
35
Stifel Financial
Missouri
$1.51M +$8.42K +2,000 +0.6%
Man Group
36
Man Group
United Kingdom
$1.46M +$1.48M +351,700 New
HF
37
HRT Financial
New York
$1.43M +$1.45M +344,811 New
Charles Schwab
38
Charles Schwab
California
$1.27M +$164K +38,975 +15%
Wellington Management Group
39
Wellington Management Group
Massachusetts
$1.25M +$48.8K +11,587 +4%
Marshall Wace
40
Marshall Wace
United Kingdom
$1.19M +$1.13M +267,344 +1,460%
Walleye Capital
41
Walleye Capital
New York
$1.18M -$1.27M -302,409 -52%
SAM
42
Simplify Asset Management
Nevada
$1.16M +$187K +44,444 +19%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$1.15M +$85.7K +20,360 +8%
Russell Investments Group
44
Russell Investments Group
United Kingdom
$1.08M +$144K +34,318 +15%
RA
45
Rosalind Advisors
Ontario, Canada
$1.04M – – –
LI
46
Latash Investments
Alaska
$1.01M – – –
Hudson Bay Capital Management
47
Hudson Bay Capital Management
Connecticut
$973K – – –
Lido Advisors
48
Lido Advisors
California
$896K +$906K +215,316 New
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$875K -$290K -68,998 -25%
AQR Capital Management
50
AQR Capital Management
Connecticut
$840K +$633K +150,347 +291%
1
2
3 4 5

AQST Hedge Fund Activity: Q2 2026 in Review

184 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2026, worth a combined $300M — up 0.31% from $299M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new AQST positions and 18 closed out — a net gain of 6 holders — while 69 added to existing stakes and 43 trimmed.

The largest buyer was Nuveen, adding an estimated $4.05M. The largest seller was Balyasny Asset Management, cutting an estimated $9.07M.

  • 184 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2026, up from 180 in Q1 2026.
  • Funds reported $300M of Aquestive Therapeutics stock for Q2 2026, up 0.31% quarter-over-quarter.
  • 24 funds opened new Aquestive Therapeutics positions in Q2 2026 and 18 closed out, a net change of +6 holders.
  • The largest Aquestive Therapeutics buyer in Q2 2026 was Nuveen, an estimated $4.05M added.
  • The largest Aquestive Therapeutics seller in Q2 2026 was Balyasny Asset Management, an estimated $9.07M sold.

Based on aggregated 13F filings for Q2 2026.